In Two Phase 3 Trials With Over 1200 Adult Patients With IBS-C

IBSRELA DEMONSTRATED SAFETY AND TOLERABILITY1

Most Common Adverse Reactions* in Patients With IBS-C in T3MPO-2 (26 Weeks)1

*Reported in at least 2% of patients treated with IBSRELA and at an incidence greater than placebo.

†The adverse reaction profile was similar during the 12-week, double-blind, placebo-controlled treatment period of T3MPO-1, with diarrhea (15% with IBSRELA vs 2% with placebo) and abdominal distension (2% with IBSRELA vs 0% with placebo) as the most common adverse reactions.

person with shield containing checkmark icon

In T3MPO-1 (12 weeks) and T3MPO-2 (26 weeks):

  • Diarrhea was typically 2,3
    • Mild-to-moderate
    • Transient (≤1 week in duration)
  • Severe diarrhea was reported in 2.5% of patients treated with IBSRELA compared with 0.2% of patients treated with placebo1
  • Discontinuation due to adverse reactions occurred in 7.6% of patients treated with IBSRELA compared with 0.8% of patients treated with placebo, with diarrhea as the most common reason for discontinuation (6.5% vs 0.7%)1

Explore IBSRELA

Find out how in  Access & Savings

References:

  1. IBSRELA [prescribing information]. Waltham, MA: Ardelyx, Inc.; 2022.
  2. Chey WD, Lembo AJ, Yang Y, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 26-week, placebo-controlled phase 3 trial (T3MPO-2). Am J Gastroenterol. 2021;116(6):1294-1303.
  3. Chey WD, Lembo AJ, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1). Am J Gastroenterol. 2020;115(2):281-293.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS

IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.

CONTRAINDICATIONS

  • IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
  • IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

WARNINGS AND PRECAUTIONS

Risk of Serious Dehydration in Pediatric Patients

  • IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years).
  • Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.

Diarrhea

Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and rehydrate patient.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions in IBSRELA-treated patients (incidence ≥2% and greater than placebo) were: diarrhea (16% vs 4% placebo), abdominal distension (3% vs <1%), flatulence (3% vs 1%) and dizziness (2% vs <1%).

INDICATION

IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

Please see full Prescribing Information, including Boxed Warning, for additional risk information.

PLEASE INDICATE WHETHER YOU ARE A US HEALTHCARE PROFESSIONAL:

Proceed